Equity Details
Price & Market Data
Price: $52.83
Daily Change: -$1.18 / 2.23%
Daily Range: $52.02 - $54.30
Market Cap: $5,095,389,696
Daily Volume: 973,650
Performance Metrics
1 Week: 0.86%
1 Month: -3.65%
3 Months: 8.19%
6 Months: -4.15%
1 Year: 40.54%
YTD: 0.74%
About CRISPR Therapeutics AG (CRSP)
Market review of CRISPR Therapeutics AG (CRSP). Current price: 52.83, daily change: -$1.18 / 2.23%. Market cap: 5,095,389,696. All performance figures are updated.
Company Details
Employees: 393
Sector: Health technology
Industry: Biotechnology
Country: Switzerland
Details
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.